Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997 Nov; 15(11):3394-8.